BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Emtricitabine/tenofovir/rilpivirine regulatory update

Gilead disclosed in its 1Q11 earnings that FDA accepted for filing and granted Priority Review to an NDA for a fixed-dose combination of rilpivirine and Truvada emtricitabine/tenofovir to treat HIV infection. Gilead resubmitted the NDA in February after...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >